Establishment of a Human iPSC- and Nanofiber-Based Microphysiological Blood–Brain Barrier System by Qi, Dianjun et al.
University of Nebraska - Lincoln
DigitalCommons@University of Nebraska - Lincoln
Chemical and Biomolecular Engineering -- All
Faculty Papers
Chemical and Biomolecular Engineering,
Department of
2018
Establishment of a Human iPSC- and Nanofiber-
Based Microphysiological Blood–Brain Barrier
System
Dianjun Qi
University of Nebraska Medical Center
Shaohua Wu
University of Nebraska Medical Center
Haishuang Lin
University of Nebraska - Lincoln, hlin9@unl.edu
Mitchell A. Kuss
University of Nebraska Medical Center
Yuguo Lei
University of Nebraska - Lincoln, ylei14@unl.edu
See next page for additional authors
Follow this and additional works at: http://digitalcommons.unl.edu/chemengall
This Article is brought to you for free and open access by the Chemical and Biomolecular Engineering, Department of at DigitalCommons@University
of Nebraska - Lincoln. It has been accepted for inclusion in Chemical and Biomolecular Engineering -- All Faculty Papers by an authorized
administrator of DigitalCommons@University of Nebraska - Lincoln.
Qi, Dianjun; Wu, Shaohua; Lin, Haishuang; Kuss, Mitchell A.; Lei, Yuguo; Krasnoslobodtsev, Alexey; Ahmed, Shaheen; Zhang, Chi;
Kim, Hyung Joon; Jiang, Peng; and Duan, Bin, "Establishment of a Human iPSC- and Nanofiber-Based Microphysiological
Blood–Brain Barrier System" (2018). Chemical and Biomolecular Engineering -- All Faculty Papers. 73.
http://digitalcommons.unl.edu/chemengall/73
Authors
Dianjun Qi, Shaohua Wu, Haishuang Lin, Mitchell A. Kuss, Yuguo Lei, Alexey Krasnoslobodtsev, Shaheen
Ahmed, Chi Zhang, Hyung Joon Kim, Peng Jiang, and Bin Duan
This article is available at DigitalCommons@University of Nebraska - Lincoln: http://digitalcommons.unl.edu/chemengall/73
Establishment of a Human iPSC- and Nanofiber-Based 
Microphysiological Blood–Brain Barrier System
Dianjun Qi†,‡,⊥, Shaohua Wu‡,§, Haishuang Lin‖, Mitchell A. Kuss‡,⊥, Yuguo Lei‡,‖,iD, Alexey 
Krasnoslobodtsev#, Shaheen Ahmed¶, Chi Zhang¶, Hyung Joon Kim‡,∇, Peng Jiang*,◦, and 
Bin Duan*,‡,⊥,◆,iD
†Department of General Practice, The First Affiliated Hospital of China Medical University, 
Shenyang, Liaoning 110001, China
‡Mary & Dick Holland Regenerative Medicine Program, University of Nebraska Medical Center, 
Omaha, Nebraska 68198, United States
⊥Division of Cardiology, Department of Internal Medicine, University of Nebraska Medical Center, 
Omaha, Nebraska 68198, United States
¶Department of Radiation Oncology, University of Nebraska Medical Center, Omaha, Nebraska 
68198, United States
∇Department of Psychiatry, University of Nebraska Medical Center, Omaha, Nebraska 68198, 
United States
◆Department of Surgery, University of Nebraska Medical Center, Omaha, Nebraska 68198, 
United States
§College of Textiles & Clothing, Qingdao University, Qingdao 266071, China
‖Department of Chemical and Biomolecular Engineering, University of Nebraska—Lincoln, 
Lincoln, Nebraska 68588, United States
#Department of Physics, University of Nebraska at Omaha, Omaha, Nebraska 68182, United 
States
◦Department of Cell Biology and Neuroscience, Rutgers University, Piscataway, New Jersey 
08854, United States
Abstract
*Corresponding Authors. peng.jiang@rutgers.edu. Phone: +1 848 445 2805 (P.J.). bin.duan@unmc.edu. Phone: +1 402 559 9637 
(B.D.).
ORCID 
Yuguo Lei: 0000-0002-7682-6912
Bin Duan: 0000-0002-5647-3793
ASSOCIATED CONTENT
Supporting Information
The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acsami.8b03962.
Demonstration of the capacity of the 3D-printed holder (AVI)
Human iPSC-ECs expressing CD31 and CD144 and the permeability coefficient of sodium fluorescein (PDF)
The authors declare no competing financial interest.
HHS Public Access
Author manuscript
ACS Appl Mater Interfaces. Author manuscript; available in PMC 2018 July 19.
Published in final edited form as:
ACS Appl Mater Interfaces. 2018 July 05; 10(26): 21825–21835. doi:10.1021/acsami.8b03962.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
The blood–brain barrier (BBB) is an active and complex diffusion barrier that separates the 
circulating blood from the brain and extracellular fluid, regulates nutrient transportation, and 
provides protection against various toxic compounds and pathogens. Creating an in vitro 
microphysiological BBB system, particularly with relevant human cell types, will significantly 
facilitate the research of neuropharmaceutical drug delivery, screening, and transport, as well as 
improve our understanding of pathologies that are due to BBB damage. Currently, most of the in 
vitro BBB models are generated by culturing rodent astrocytes and endothelial cells, using 
commercially available transwell membranes. Those membranes are made of plastic biopolymers 
that are nonbiodegradable, porous, and stiff. In addition, distinct from rodent astrocytes, human 
astrocytes possess unique cell complexity and physiology, which are among the few characteristics 
that differentiate human brains from rodent brains. In this study, we established a novel human 
BBB microphysiologocal system, consisting of a three-dimensionally printed holder with a 
electrospun poly(lactic-co-glycolic) acid (PLGA) nanofibrous mesh, a bilayer coculture of human 
astrocytes, and endothelial cells, derived from human induced pluripotent stem cells (hiPSCs), on 
the electrospun PLGA mesh. This human BBB model achieved significant barrier integrity with 
tight junction protein expression, an effective permeability to sodium fluorescein, and higher 
transendothelial electrical resistance (TEER) comparing to electrospun mesh-based counterparts. 
Moreover, the coculture of hiPSC-derived astrocytes and endothielial cells promoted the tight 
junction protein expression and the TEER value. We further verified the barrier functions of our 
BBB model with antibrain tumor drugs (paclitaxel and bortezomib) and a neurotoxic peptide 
(amyloid β 1–42). The human microphysiological system generated in this study will potentially 
provide a new, powerful tool for research on human BBB physiology and pathology.
Graphical abstract
Keywords
electrospinning; 3D printing; human induced pluripotent stem cells; transepithelial electrical 
resistance; drug screening
1. INTRODUCTION
The blood–brain barrier (BBB) is a highly selective, semipermeable membrane barrier that 
strictly regulates molecular exchange and separates the circulating blood from the brain.1 
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BBB is mainly composed of endothelial cells (ECs), pericytes, astrocytes, and basal 
membrane (BM) (i.e., a thin layer of fibrous extracellular matrix [ECM]).2,3 ECs provide 
tight and adherent cellular junctions and form a diffusion barrier, which strongly regulates 
the penetration of blood-borne molecules into the brain.4,5 Astrocytes are essential for the 
formation and maintenance of the BBB by leading to closer tight junctions, secreting growth 
factors and cytokines, and providing the cellular link to the neurons.1,6 Apart from the 
cellular components, BM is another vital component of the BBB, playing both structural and 
modulatory roles.7 BM and its ECM proteins provide physical support and anchor points for 
ECs and astrocytes and regulate cellular interaction and signaling.8,9
In the past few decades, many in vitro BBB models have been developed to imitate the 
human BBB because animal models do not always reflect the biology of the BBB-related 
human diseases.10,11 Currently, the basic structure of the BBB in vitro model includes a 
transwell membrane insert and seeded cells.10,12 Primary brain ECs isolated from human 
brain tissue were monocultured or co/tricultured with pericytes on one side of the insert 
membrane and astrocytes (sometimes with neurons) on the other side.13–16 One trend is the 
utilization of human pluripotent or adult stem cells instead of primary cells or cells 
immortalized by the introduction of genes that deregulate the cell cycle because of the 
limitations that primary cells have, such as low availability and reproducibility, and that 
immortalized human cells are unable to form strong barrier properties because of the loss of 
important phenotypes, such as tight junctions.17–19 Human pluripotent stem cells, especially 
human induced pluripotent stem cells (hiPSCs), are a promising stem cell source and have 
enormous potential for the development of human BBB in vitro models.19,20 Human iPSC-
based BBB models have been generated, but many studies used a coculture with mixed 
species, such as rat astrocytes.20,21 The human brain is far more complex than the rodent 
brain, with the complexity of astrocytes being among the key characteristics that 
differentiate human brains from rodent brains.22,23 It is thus imperative to develop robust 
and reproducible BBB models with a combination of human ECs and astrocytes and even 
with human pericytes and neurons.16 In addition, an hiPSC-based BBB model will be 
beneficial and will provide a possible strategy for personalized drug screening for BBB-
related diseases.
Another major limitation of the current in vitro BBB model is the use of plastic and porous 
transwell membrane inserts, which are standard, commercially available membranes made 
from polyethylene terephthalate (PET),24 polycarbonate,25 or polytetrafluoroethylene.26 
These materials cannot fully mimic human BM because they are stiff, less porous, and lack a 
three-dimensional (3D) structure comparable to native tissue.27,28 Most importantly, these 
materials cannot be remodeled by cells and lack cell–material interactions. The BBB is 
dynamically maintained and regulated by a complex cross talk between ECs and cells from 
the neurovascular unit.29 Therefore, 3D substrates, which are biodegradable and able to 
support cell remodeling and EC–astrocyte interaction, are more appropriate for in vitro BBB 
model development. Recently, several groups have implemented electrospinning, which is a 
versatile technique used to fabricate scaffolds composed of a 3D, porous, and nano/
microfibrous matrix, to mimic BM structure in BBB models.30–32 However, the 
transendothelial electrical resistance (TEER), which is a sensitive and reliable indicator of 
the integrity of the tight junction dynamics in BBB, was relatively low, probably due to the 
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poor integration of the electrospun meshes with the transwell insert and the chosen cell 
types.
In this study, we designed and fabricated a 3D nanofibrous BM-like matrix by combining 
electrospinning and 3D printing techniques and further developed an in vitro BBB model by 
coculture of hiPSC-derived ECs and astrocytes (hiPSC-ECs, hiPSC-Astro). We 
systematically characterized the properties of this BBB model and further verified its barrier 
functions to antiglioblastoma (GBM) drugs and a neurotoxic peptide.
2. EXPERIMENTAL SECTION
2.1. Preparation of a 3D Nanofibrous Matrix on the 3D-Printed Holder
The holder with diameter of 7 mm, thickness of 1 mm, and pore size of 1 mm × 1 mm 
(Figure 1A) was designed and 3D-printed by using a digital light processing-based 3D 
printer (Vida, EnvisionTec) and a biocompatible light curing methacrylic-/acrylic-resin 
(EnvisionTec, with components of urethandimethacrylate, neopentyglcol-diacrylate, and 
phosphinoxide). Two handles were designed to facilitate the handling by tweezers. The 
holder can perfectly fit into the commercially available transwell insert (24-well, Corning), 
with the removal of the inside PET membrane. Then, the 3D-printed holders were mounted 
onto the grounded flat surface, which was covered with aluminum foil, to collect the 
electrospun poly lactic-co-glycolic acid (PLGA) fibers (Figure 1B). PLGA (82:18; L-lactide/
glycolide, Corbion Purac Biomaterials) was dissolved in 1,1,1,3,3,3-hexafluoroisopropanol 
(HFIP) to prepare a 10% solution for electrospinning. Then, 10 mL of the solution was 
loaded into a plastic syringe equipped with a 23 gauge needle made of stainless steel. The 
needle was connected to a high-voltage supply (ES30P-5W, Gamma High Voltage Research 
Inc.)33 and positive voltage was applied to the reservoir at approximately 12 kV. The 
solution was continuously supplied using a syringe pump (Model 78-01001, Fisher 
Scientific) at a rate of 0.8 mL/h. The distance between the needle tip and the collector was 
15 cm. Figure 1C shows the 3D-printed holders with and without the electrospun PLGA 
mesh. The holders fit well into the transwell insert (Figure 1D).
2.2. Scanning Electron Microscopy Observation
The morphology of PLGA nanofibers was characterized using scanning electron microscopy 
(SEM) (FEI Quanta 200, Japan). The electrospun PLGA mesh was peeled from the 3D-
printed holder and was sputter coated with gold under a nitrogen atmosphere and imaged 
using 12.5 kV accelerating voltage. To image and measure the thickness, the peeled PLGA 
mesh was sandwiched between two holders and was sectioned by using a cryotome to 
expose the mesh in the pore area. The diameter of the fibers and the thickness of the mesh 
were measured by using Image J software. To observe the morphology of iPSC-ECs on the 
PLGA mesh, samples were fixed by 4% (v/v) paraformaldehyde (PFA) for 4 h and then 
dehydrated, critical point-dried, and gold-sputtered for SEM imaging.
2.3. Characterization of Mechanical Properties
Uniaxial tensile tests were performed using a Shakopee MN55379 tester with a custom grip 
gap of 1 cm. The 3D-printed holders were removed from electrospun PLGA meshes and the 
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meshes were cut into pieces (10 mm in width and 30 mm in length) with the holder area in 
the center (Figure 2D). The thickness of the scaffolds was measured with an electronic 
digital clipper. A displacement of 1 mm/min was applied to each specimen and the data were 
collected until a break occurred. The Young’s modulus, breaking strength, and breaking 
strain were measured and calculated.
The stiffness of the PLGA meshes was characterized via atomic force microscopy (AFM) 
nanoindentation measurements, using a Force Robot 300 instrument (JPK Instruments, 
Berlin, Germany). The meshes were affixed to microscope glass slides and transferred to an 
atomic force microscope chamber for measurements. All of the measurements were taken at 
room temperature. A silicon-nitride AFM probe—PT.GS (Novascan Technologies, Inc, 
Boone, IA), with a glass spherical particle attached, was used for indentation measurements. 
The probe had a deflection sensitivity of 24.6 nm/V, which was calibrated against a hard 
(mica) surface. The spring constant of the cantilever was obtained using a thermal method 
and amounted to 46.3 mN/m. Samples were visualized with a built-in charge-coupled device 
camera in the atomic force microscope head. Different sections (pore region vs strut region) 
of the electrospun mesh were identified based on their contrast. The indentation 
measurements were performed on a 10 × 10 µm area using a 20 × 20 grid. Such a large area 
allowed us to account for spatial heterogeneity of the sample by statistically averaging the 
measured points on the grid. The mechanical properties of each point on the grid were 
probed by one indentation cycle with loading/unloading curves. During loading, the probe 
was pushed into the mesh to a 5 nN loading force with a speed of 1 µm/s, which was 
followed by an unloading curve with the same speed. Loading force (5 nN) corresponds to 
~108 nm of indentation depth, which was chosen to be small enough to be compared to the 
thickness of the meshes to avoid any influence of the underlying surface. Collected curves 
were analyzed with the JPK Data Processing software package. The sample stiffness 
(Young’s modulus) was obtained by fitting the loading curves to a Hertz–Sneddon model 
using spherical tip geometry. The fitting was done with a Poisson ratio of 0.50 and calibrated 
parameters of the tip geometry, namely a tip radius of 5 µm.
2.4. Cell Culture and Seeding
Two healthy hiPSC lines were reprogrammed from fibroblasts obtained from healthy 
individuals, as described in our previous study.34 An embryoid body-based differentiation 
procedure was used for the differentiation of these hiPSCs to neural progenitor cells (NPCs) 
(hiPSC–NPCs) and then astrocytes (hiPSC-Astro) and neurons.34–37 The hiPSC–NPCs were 
cultured and expanded in the growth medium, containing a mixture (1:1) of Dulbecco’s 
modified Eagle medium (DMEM)/F12 and Neurobasal medium, supplemented with 1× N2, 
1× B27, 20 ng/mL basic fibroblastic growth factor (bFGF), and 1% Pen/Strep at 37 °C in a 
5% CO2 atmosphere. The hiPSC–NPCs were harvested using TrypLE (Gibco), resuspended 
in growth medium, and seeded (5 × 104 cells per well) in 24-well plates with a Matrigel 
coating. Y-27632 (Tocris, 10 µM, a ROCK inhibitor) was added to the medium on the first 
day of seeding. To induce astroglial differentiation, the hiPSC–NPCs were then cultured in a 
medium containing DMEM/F12 (HyClone), 10 ng/mL bone morphogenetic protein 
(BMP)-4 (PeproTech), 1× N2 (Thermo Fisher Scientific), 1× B27 (Thermo Fisher 
Scientific), 20 ng/mL bFGF (Peprotech), and 1% Pen/Strep (Invitrogen). To induce neuronal 
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differentiation, the hiPSC–NPCs were cultured in a medium consisting of 50% DMEM/F12, 
50% Neurobasal medium, 1% N2, 2% B27, 10 µM cAMP (Sigma), 200 nM Ascorbic Acid 
(Sigma), 10 ng/mL brain-derived neurotrophic factor (Peprotech), 10 ng/mL glial cell line-
derived neurotrophic factor (Peprotech), and 1% Pen/Strep. Astroglial and neuronal 
differentiation was conducted for 2–3 weeks at 37 °C in a 5% CO2 atmosphere.
For EC differentiation, hiPSCs were dissociated with Accutase and plated on Matrigel at a 
density of 40 000 cells/cm2 in E8 with 10 µM Y-27632. After 24 h, the medium was 
replaced with differentiation medium, consisting of a 1:1 mixture of DMEM/F12 with 
GlutaMAX and Neurobasal media, supplemented with 1× N2 and 1× B27 with 8 µM 
CHIR99021 (LC laboratories) and 25 ng/mL BMP-4. After 3 days, the differentiation 
medium was replaced by EC induction medium, consisting of StemPro-34 SFM medium 
(Life Technologies), supplemented with 200 ng/mL VEGFA (PeproTech) and 2 µM 
Forskolin (Sigma). The induction medium was changed after 1 day. On day 6 of 
differentiation, the hiPSC–ECs were replated on human fibronectin (Sigma)-coated dishes at 
a density of 25 000 cells/cm2 in EC growth medium 2 (EGM-2, Lonza). The derived hiPSC-
ECs were positive to CD31 and CD144 (Figure S1). The hiPSC-derived cells were harvested 
using the dissociation reagent TrypLE, centrifuged, and resuspended in DMEM/F12 basal 
medium or EGM-2. Then, the cells were surface-seeded onto the Matrigel (Corning)-coated 
electrospun PLGA matrix on the holder. Each insert was seeded with 5 × 105 cells, which 
were resuspended in 20 µL of medium. After incubation in the incubator for 3 h to allow cell 
attachment, the corresponding medium was added. The medium was replaced every second 
day before seeding and every day after seeding. For the coculture of hiPSC-ECs and hiPSC-
Astro, the hiPSC-Astro were first seeded on the bottom side of the electrospun PLGA matrix 
on the holder inserted into the traswell. One day later, hiPSC-ECs were seeded on the top 
side of the electrospun PLGA mesh. The upper chamber was filled with EGM-2, and the 
lower chamber was filled with hiPSC-Astro medium. The cell culture plates were incubated 
at 37 °C in a 5% CO2 incubator for up to 7 days.
U87MG GBM cells (ATCC) were cultured in DMEM/F12, with 10% (v/v) fetal bovine 
serum (Gibco) and 1% Pen/Strep at 37 °C in a 5% CO2 atmosphere. Each well of the 24-
well plate was seeded with 1 × 104 cells after harvesting with trypsin, centrifugation, and 
resuspension in the growth medium. The medium was replaced every other day.
For the triculture of hiPSC-ECs, hiPSC-Astro, and hiPSC–NPCs or U87MG, hiPSC–NPCs 
or U87MG were cultured in a 24-well plate, in the lower chamber, with neuronal 
differentiation medium or astroglial differentiation medium, respectively. The BBB model 
with hiPSC-ECs and hiPSC-Astro was cultured in the transwell insert with the PLGA mesh 
and 3D-printed holder. The upper chamber was filled with EGM-2.
2.5. Cell Viability
The viability of cells was determined using a Live/Dead assay (Invitrogen) 3 days after 
seeding, as previously described,38 and fluorescence images were obtained using confocal 
laser scanning microscopy (LSM 710, Carl Zeiss).
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2.6. Immunofluorescence Staining
For immunofluorescence (IF) staining, samples were fixed in 4% (v/v) PFA, permeabilized 
in 0.2% Triton X-100 for 10 min, and then blocked with 1% bovine serum albumin 
overnight at 4 °C. The samples were incubated with primary antibodies to CD31 (1:100, 
Invitrogen), von Willebrand Factor (vWF) (1:100, Sigma), glial fibrillary acidic protein 
(GFAP) (1:200, Sigma), S100B (1:500, Cell Signaling), vimentin (1:100, Sigma), Caspase-3 
(1:100, Cell Signaling), Tuj-1 (1:100, Cell Signaling), and zonula occluden-1 (ZO-1, 1:100, 
Thermo Fisher Scientific) overnight at 4 °C. Secondary fluorescent antibodies (1:100) were 
incubated for 2 h and nuclear counterstaining (via Draq 5, 1:1000, Biostatus) was performed 
for 30 minutes at room temperature. Then, the samples were imaged with a Zeiss 710 
confocal laser scanning microscope.
2.7. TEER Analysis
TEER is a noninvasive way to measure the electrical resistance across a cellular monolayer 
or cell coculture. The TEER values of a blank mesh (without any cells), a mesh with hiPSC-
Astro, and BBB tissue (with both hiPSC-ECs and hiPSC-Astro) were measured by using a 
Millicell electrical resistance apparatus (Endohm-6 and EVOM, World Precision 
Instruments). The average TEER value was monitored and analyzed for 7 days while being 
performed in triplicate. The TEER value was calculated as follows:
TEER value (Ω · cm2) = TEER (Ω) × surface area (0.385 cm2)
2.8. Sodium Fluorescein Permeability Studies
Sodium fluorescein permeability studies were conducted after the TEER reached maximum 
values. The engineered BBB tissues were washed with Dulbecco’s phosphate-buffered 
saline (DPBS) (Gibco), and then, 200 mL of sodium fluorescein (Sigma), diluted in DPBS, 
was loaded into the upper chambers. DPBS (1000 µL), without sodium fluorescein, was 
loaded into the lower chambers. The whole setup was incubated in the incubator for 30 min. 
After incubation, the DPBS in the lower chamber was collected and the concentration of 
sodium fluorescein was determined using a microplate reader (Ex(λ) 485 nm, Em(λ) 535 
nm, BioTek). The permeability coefficient (cm/s) was calculated as follows
Permeability coefficient =
VAb × CAb
S × C × t
VAb is the volume of the lower chamber, CAb is the concentration of sodium fluorescein in 
the lower chamber, S is the surface area of the filter, C is the concentration of sodium 
fluorescein, and t is the incubation time.
2.9. Toxicity Treatment
We examined the barrier function of the engineered BBB model by the addition of toxic 
drugs and the evaluation of the subsequent cell response. We tricultured BBB tissues with 
U87MG or hiPSC–NPCs and added an anti-GBM drug or human β-amyloid 1–42 (Aβ, 
Genscript) in the upper chamber, with the accommodation of the BBB tissue. We used an 
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empty mesh (without cell culture) as a positive control and used the groups without the 
addition of drugs as a negative control. For the toxicity treatment, U87MG cells were 
cultured at a density of 1 × 104 cells/well in 24 wells at 37 °C. Then, a paclitaxel (PTX) 
(Selleckchem, 1 µg/mL, or 2 µg/mL) or bortezomib (BTZ) (Selleckchem, 4 µg/mL, or 8 
µg/mL) solution was added to the upper chamber with BBB tissue and tricultured with 
U87MG for 24 h. For the neuronal toxicity treatment, human Aβ was dissolved in PBS (100 
µg/mL) and then incubated at 37 °C for 4 days to initiate aggregate formulation.39 Human 
iPSC–NPCs were subjected to neuronal differentiation for 14 days and tricultured with BBB 
tissue. Then, the aggregated Aβ (4 µg/mL) was added for 48 h culture.
2.10. Lactate Dehydrogenase Assay
Cytotoxicity was estimated by determining lactate dehydrogenase (LDH) released into the 
culture medium. Supernatants and lysates of U87MG cells (with or without PTX and BTZ) 
and hiPSC–NPC-induced neuron cells (with or without Aβ) were collected. An LDH-based 
CytoTox 96 Assay (Promega) was performed according to the manufacturer instructions. 
The percentage of cytotoxicity (%) was calculated as follows
Percentage of cytotoxicity (%) =
LDH activity supernatant (OD490)
LDH activity cell lysate (OD490)
× 100
2.11. 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium Bromide Assay
We also evaluated U87MG cell viability with PTZ and BTZ treatments, with or without 
engineered BBB tissue, by using an 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay, as described previously.40 Briefly, 25 µL of MTT solution (10 
mg/mL) was added into each well and incubated for 4 h. Then, 500 µL of dimethyl sulfoxide 
(Sigma, USA) was added to dissolve the formazan crystals after the medium was removed. 
The absorbance at 540 nm was measured using the microplate reader.
2.12. Statistical Analysis
All quantitative data is expressed as the mean ± standard deviation. Statistical analysis was 
performed using analysis of variance with Scheffé post-hoc tests. P values <0.05 were 
considered statistically significant.
3. RESULTS
3.1. Fabrication and Characterization of the Nanofibrous PLGA Mesh on the 3D-Printed 
Holder
We first 3D-printed a holder that can perfectly fit into the 24-well transwell frame (Video 1). 
The struts were designed to hold the electrospun fibers and to prevent leaking due to the 
pressure generated in the transwell. The pores on the holders guarantee the permeability of 
the whole device. Then, a thin layer of a nanofibrous PLGA mesh was electrospun on the 
surface of the holders (Figure 1B). Figure 1C shows the 3D-printed holder with (left) and 
without (right) the electrospun PLGA mesh. The electrospun PLGA mesh on the holder was 
inserted into the 24-well transwell, after removing the transwell membrane (Figure 1D).
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As shown in SEM micrographs in Figure 2A,B, a fibrous morphology of the electrospun 
PLGA mesh was observed. The PLGA nanofibers in the pore area were thinner than those in 
the strut area. The diameter of the PLGA nanofibers was around 800 nm, and the thickness 
of the electrospun PLGA mesh in the pore area was around 30 µm (Figure 2C). The thinner 
thickness facilitated more cell–cell contact between hiPSC-ECs and hiPSC-Astro, which 
may improve BBB barrier integrity.41
We further peeled the PLGA mesh from the holder and conducted a tensile test and 
nanoindentation to measure the bulk Young’s modulus (Figure 2D) and local stiffness, 
respectively. The typical stress–strain curve was shown in Figure 2E. The Young’s modulus 
of the PLGA mesh was 53.8 ± 4.5 MPa, which is a little bit higher than the in vivo human 
BBB (an estimated Young’s modulus around 8–10 kPa) but much smaller than the 
commercial PET transwell membrane (~2 GPa).32 The nanoindentation results showed that 
the stiffness in the pore area was significantly lower than that in the strut area (Figure 2F). 
This is probably due to the thickness difference between the two areas. Taken together, we 
generated an electrospun PLGA mesh onto a 3D-printed holder that fits into the transwell 
frame. The nanofibrous PLGA mesh has a thin thickness, sufficient mechanical properties, 
and adequate flexibility.
3.2. Generation of the hiPSC-Based BBB Model
To create the BBB model with hiPSC-derived cells, we first seeded hiPSC-ECs and hiPSC-
Astro separately onto the PLGA meshes. As shown in Figure 3A, both the hiPSC-ECs and 
hiPSC-Astro had high cell viability on the PLGA meshes. After 3 day culture, IF staining 
showed that a large number of hiPSC-ECs and hiPSC-Astro spread over the surface of the 
electrospun mesh (Figure 3B). Human iPSC-ECs were subconfluent because of the large 
seeding density and were positive for CD31 and vWF expression, showing a well-organized 
and continuous cell–cell interaction with very few gaps (Figure 3B). Human iPSC-Astro 
were less confluent and were positive for the astrocytes marker, that is, GFAP and S100B 
(Figure 3C).
A coculture of hiPSC-ECs and hiPSC-Astro on the electrospun PLGA mesh was achieved 
by seeding the two cell types on the two opposite sides of the PLGA mesh as shown in 
Figure 4A. Figure 4B shows confocal images of cocultured cells on the PLGA mesh. After 3 
day coculture, the BBB tissues showed positive expression of the astrocyte markers GFAP 
and S100B, EC junction marker CD31, and glycoprotein vWF. Volume-rendered side views 
clearly showed two cell layers with the electrospun meshes sandwiched between (Figure 
4B). Importantly, hiPSC-ECs in the coculture system were positive to ZO-1 (Figure 4C), 
which is one of the major tight junction proteins between brain ECs.42 The hiPSC-ECs 
showed an extensive spreading morphology on the PLGA mesh and had close interactions 
with the PLGA nanofibers (Figure 4D). Notably, many hiPSC-ECs had cell–cell interaction 
and junctions. It seemed that they were not totally confluent and there was still some space 
uncovered by the cells, but it is possible that cells had interaction under the fibrous scaffold 
surface because many cells penetrated the fibers. We further characterized the physical 
properties, including TEER values and permeability coefficient, of the BBB model. As 
expected, the empty mesh, without cells, and hiPSC-Astro alone had low TEER values 
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(Figure 4E). The addition of hiPSC-ECs significantly increased TEER, and the TEER also 
dynamically changed with culture time. The TEER values significantly increased from 119.0 
± 15.8 Ω·cm2 at day 1 to 232.8 ± 33.1 Ω·cm2 at day 3, indicating tightening of hiPSC-EC 
cell-to-cell contacts, and then gradually fell back to 181.3 ± 17.1 Ω·cm2 at day 7. A similar 
trend of TEER value change has been reported in other transwell-based BBB models, using 
both iPSC-based cells and primary cells.21,43 The permeability of our in vitro BBB model to 
sodium fluorescein was investigated to assess barrier integrity at the third day, which had the 
peak TEER value, after coculture. As shown in Figure 4F, the permeability coefficient of our 
BBB model was 2.6 ± 0.4 × 10−6 cm/s, which was significantly lower than the empty 
counterparts (80.0 ± 8.0 cm/s). In addition, the permeability coefficient did not significantly 
change over time from 30 min to 3 h (Figure S2).
3.3. Barrier Effect of the BBB Model on Anti-GBM Drugs
We evaluated the barrier functions of the hiPSC- and PLGA mesh-based BBB model to 
block brain cancer drugs. In this study, we used PTX and BTZ as model drugs, which are 
widely used as anticancer drugs to treat primary and metastatic brain cancer.44,45 Both PTX 
and BTZ have limited penetration capacities through the BBB.46,47 We thus conducted a 
triculture BBB model consisting of hiPSC-ECs and hiPSC-Astro with U87MG cells, as 
shown in Figure 5A. We then added PTX or BTZ and evaluated the U87MG response and 
TEER change after 1 day culture. Under a light microscope, U87MG cells in the control 
group, without the addition of anti-GBM drugs, showed a normal spreading morphology 
(Figure 5B). In the BBB group with a lower dose of PTX (1 µg/mL), U87MG cells had a 
slightly round-up morphology, whereas in the empty mesh group without cells, U87MG 
cells had fewer numbers, smaller size, and a much rounder morphology. For IF staining, 
U87MG cells were positive to vimentin, and more apoptotic cells were positive for active 
Caspase-3 in the empty mesh group. In contrast, less active Caspase-3 positive cells were 
observed in the control and BBB groups. With the addition of BTZ (4 µg/mL), the cell 
number decreased, and the active Caspase-3 positive cell number increased. This was similar 
to the effect of the addition of PTX (Figure 5B), but the U87MG cells acquired a spindle-
like morphology, especially in the empty mesh group. A similar observation was also 
reported by other researchers.48 This is probably because BTZ activates autophagy of 
subconfluent U87MG cells, which are subject to morphological and ultrastructural changes.
48
 For the LDH cytotoxicity assay, the percentage of cytotoxicity of U87MG cells in the 
empty mesh group was significantly higher than those in the control group and BBB group 
(Figure 5C), but there was no obvious difference between the control group and BBB group. 
Similarly, MTT results showed that U87MG cell viability statistically decreased with the 
addition of PTX and BTZ in the empty mesh group, with very limited barrier function 
(Figure 5D). The U87MG cells in the control and BBB groups had comparable metabolic 
activity. We further evaluated the TEER value changes after the addition of PTX and BTZ 
and also assessed the change with anti-GBM drug doses (Figure 5E). The TEER values just 
slightly decreased with a lower dose, but a significant decrease of the TEER values was 
observed with a higher dose of anti-GBM drugs. The dose-dependent decrease of TEER 
values indicated that both PTX and BTZ treatments with high doses compromised the BBB 
integrity.
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3.4. Barrier Effect of the BBB Model on Aβ
Dysfunction of the BBB is involved in the pathogenesis of several neurological diseases, 
including brain trauma, multiple sclerosis, and Alzheimer’s disease (AD).49 For example, 
AD brains are highly associated with leakages of blood-derived molecules, BBB breakdown, 
and neurovascular unit dysregulation.50,51 The extracellular plaques of Aβ and 
neurofibrillary tangle formation in the brain are two major pathological hallmarks in AD.52 
Aβ is a small peptide (~4.5 kDa) that circulates in plasma, cerebrospinal fluid, and brain 
interstitial fluid.53,54 Normally, Aβ clearance and degradation are regulated by several 
mechanisms, such as Aβ protease degradation, low-density lipoprotein receptor-related 
protein 1 binding, the efflux by transport of Aβ across the BBB into the blood circulation, 
and the uptake and phagocytosis of by glia cells.53,55,56 To verify the Aβ clearance capacity 
of the BBB model, we tricultured and engineered the BBB model consisting of hiPSC-ECs 
and hiPSC-Astro with hiPSC–NPCs (Figure 6A). The hiPSC–NPCs were induced for 
neuronal differentiation for 14 days before triculture. After 14 day neuronal differentiation, 
hiPSC–NPCs were positive for Tuj-1 and the axons were clearly observed (Figure 6B, first 
panel). Then, soluble oligomeric Aβ was added into the transwell insert with engineered 
BBB. After 2 day culture, Aβ aggregates were clearly observed in the empty mesh group but 
not in the control and BBB groups (Figure 6B). The human neurons differentiated from 
hiPSC–NPCs showed significantly higher cytotoxicity with Aβ aggregates in the empty 
mesh group, and there was no obvious difference between the control and BBB groups 
(Figure 6C).
4. DISCUSSION
In vitro BBB models are important tools to develop and evaluate novel 
neuropharmaceuticals and to study the fundamental and pathological mechanisms of BBB-
related neurological diseases.19,57 Current in vitro BBB models are usually based on 
commercially available plastic and porous transwell membranes. In this study, we designed 
and 3D-printed a holder that can support an electrospun PLGA mesh and can perfectly fit 
into the transwell insert. The whole device, with coculture of hiPSC-ECs and hiPSC-Astro, 
served as a BBB model. The nanofibrous PLGA mesh is biodegradable, mechanically 
robust, and flexible. Therefore, the electrospun PLGA mesh can better mimic the BM in 
native BBB and enhance cell–cell and cell–BM interactions in the neurovascular unit. A 
similar approach has also been presented by Bischel et al.55 We implemented the 3D-printed 
holder to support the PLGA mesh and to disperse the pressure and thus achieved 
significantly improved TEER values. In addition, we used hiPSCs as the cell resource for 
creating a reproducible and robust hiPSC-derived BBB model. Compared to other cell 
sources, the pluripotent nature of hiPSCs allows for the generation of various cells in the 
neurovascular unit with larger scale, a higher purity, and repeatability.19,56
In the current study, we confirmed that hiPSC-ECs were the major contributor of TEER and 
the coculture of hiPSC-ECs and hiPSC-Astro enhanced the expression of tight junction 
proteins. Similarly, Yamamizu reported that hiPSC-ECs were endowed with features 
consistent with brain ECs, including a high expression of nutrient transporters and efflux 
transporters and a strong barrier function, based on tight junctions.16 In addition, hiPSC-ECs 
Qi et al. Page 11
ACS Appl Mater Interfaces. Author manuscript; available in PMC 2018 July 19.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
cocultured with primary rat astrocytes or C6 rat glioma cells also showed brain EC 
phenotypes.20,57 A hallmark of the BBB is a high TEER because of the tight junctions 
between ECs to maintain barrier integrity. In the current study, although the TEER value was 
lower than the native BBB (~1000–2000 Ω·cm2),10,12 it is still within the reported range for 
in vitro BBB models.19,58,59 Notably, the TEER values of our system were higher than those 
of the electrospun mesh-based counterpart32 and some reported transwell membrane-based 
BBB models with primary human brain ECs58,60 or hiPSC-derived brain ECs.16 For 
example, the electrospun gelatin–genipin biopapers with coculture of primary human 
astrocytes and human brain microvascular ECs were reported to have TEER values of 10–30 
Ω·cm2.30,32 In addition to the implementation of multiple types of cells from different 
sources, our system with a 3D-printed holder, electrospun mesh, and transwell frame can 
provide better sealing and integration. Future work is warranted to modify the PLGA surface 
to promote tight junction protein expression and maturation of brain ECs. Other 
neurovascular cell types, such as pericytes, may need to be incorporated to stabilize EC and 
increase the TEER value.
We verified the barrier function of our BBB model by using two types of molecules: (i) anti-
GBM drugs, including PTX (mitotic inhibitor) and BTZ (proteasome inhibitor), and (ii) a 
neurotoxic peptide (i.e., Aβ 1–42, one of the most common and the most aggregatable 
isoform). Because of the presence of BBB, the delivery of therapeutic agents to brain 
cancers (both primary tumors and metastases) has long been a problematic issue.61,62 Both 
PTX and BTZ have poor penetration across the BBB into brain tumors, mainly because the 
active efflux transporters (such as p-glycoprotein and multidrug resistance proteins) 
transport those antineoplastic drugs back to the blood stream.46,47,63 We demonstrated that 
our BBB model had positive barrier functions to block PTX and BTZ transportation to work 
on the GBM cells underneath, which is similar to the limited therapeutic effects of PTX and 
BTZ on GBM in vivo.64,65 Our results also demonstrated that a lower dose of PTX and BTZ 
had a slight effect on the TEER value of the BBB model, with a short time period of 
administration, whereas a higher dose significantly affected the BBB integrity. During the 
AD progression, BBB plays an important role in regulating the dynamic balance of Aβ in 
the brain.53,66 Cerebrovascular dysfunction may impair the clearance of Aβ from the brain 
and increase the penetration of peripheral Aβ into the brain, leading to elevated Aβ 
deposition in neurons.67,68 In the present study, we found that our BBB model can 
effectively reduce the penetration of the Aβ oligomer into the neurons differentiated from 
hiPSC–NPCs.
Our BBB model, with a nanofibrous matrix and hiPSC-derived neurovascular cells, has great 
potential to implement patient-specific iPSCs for anti-GBM drug screening and gaining new 
insights into BBB-related neurological diseases. Although our human BBB model in its 
current format involves a nanofibrous matrix, which is more similar to native BM compared 
to plastic transwell membranes, future studies are required to construct a 3D BBB model 
with a BM-like matrix and all four neurovascular cell populations (i.e., brain ECs, pericytes, 
astrocytes, and neurons). The combination of 3D printing, electrospinning, and/or other 3D 
biofabrication techniques will enable us to generate more complex structures to better 
accommodate the cells. In addition, pericytes have been successfully generated from hiPSCs 
and hopefully can be employed to further improve the TEER value.16,69
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5. CONCLUSIONS
In the current study, we designed and 3D-printed a holder to accommodate an electrospun 
PLGA mesh and fit into a tranwell insert frame, and we further generated an in vitro human 
BBB model by bilayer coculture of hiPSC-ECs and hiPSC-Astro. The PLGA nanofibrous 
mesh had thin thickness, sufficient mechanical properties, adequate flexibility, and supported 
the growth and phenotypic expression of hiPSC-ECs and hiPSC-Astro. We demonstrated 
that the BBB model had strong barrier function and normal permeability. The coculture of 
hiPSC-ECs and hiPSC-Astro promoted tight junction protein expression and TEER value. 
Our BBB model, with biomimetic in vivo function and integrity, had significant barrier 
effects on anti-GBM drugs (PTX and BTZ) and the neurotoxic peptide (Aβ 1–42) 
transportation to GBM cells and hiPSC–NPC-derived neurons. The implementation of 
hiPSCs to derive neurovascular cells enables us to generate a BBB model that is more 
similar to human physiology not only due to the cell availability and function but also its 
potential of being disease-specific and patient-specific. This strategy and model will be 
useful for the study of intracranial drug delivery and screening and for research on human 
BBB physiology and pathology.
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Figure 1. 
Fabrication of the insert consisting of a 3D-printed holder and an electrospun PLGA mesh 
for the BBB model: (A) design of a holder that can fit into a commercial transwell frame. 
The holder has pore and strut areas with two handles for handling; (B) schematic of 
electrospinning PLGA nanofibers onto the holder. The holder is fixed onto the aluminum 
foil on the collector; (C) the insert with the PLGA mesh (left) and an empty holder without 
the mesh (right); and (D) the inserts were placed into the commercial transwell frame after 
removing the plastic membranes. Left: insert with the holder and PLGA mesh; Right: insert 
only.
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Figure 2. 
Characterization of nanofibrous PLGA meshes electrospun onto the holders: (A–C) typical 
SEM micrographs of the PLGA mesh. (A) Overview of the morphology. Two areas with 
similar fibrous morphology but different thicknesses were observed. The white arrow 
indicates the strut region with a thicker thickness, and the red frame and blue arrow indicate 
the pore region with thinner thickness; (B) close view of the pore region; (C) side view of 
the pore region, showing the thickness of the PLGA mesh; (D) schematic of the tensile test 
of PLGA meshes peeled from holders; (E) typical tensile stress–strain curve; and (F) 
stiffness of the pore region and strut region tested by nanoindentation (~50 points from three 
different samples, **p < 0.01).
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Figure 3. 
Cell viability and phenotypic marker expression of hiPSC-ECs and hiPSC-Astro on 
nanofibrous PLGA meshes: (A) Live/Dead assay images (scale bar: 100 µm) and (B,C) 
typical IF images, showing the expression of vWF (red), CD31 (green) for hiPSC-EC and 
S100B (red), GFAP (green) for hiPSC-Astro (scale bar: 100 µm).
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Figure 4. 
Generation and characterization of the in vitro BBB model: (A) schematic of a coculture of 
hiPSC-ECs and hiPSC-Astro on the PLGA mesh that was electrospun onto the 3D-printed 
holder and fit into the transwell frame. Human iPSC-ECs were cultured on the top side of 
the PLGA mesh and conditioned in EGM in the upper chamber, whereas hiPSC-Astro were 
cultured in the bottom side in astrocyte medium in the lower chamber; (B) IF staining of 
cocultured hiPSC-ECs and hiPSC-Astro after 7 day culture. In the upper panel, the BBB 
model was costained with CD31 for hiPSC-ECs and GFAP for hiPSC-Astro, whereas in the 
lower panel, S100B and vWF were stained for hiPSC-Astro and hiPSC-ECs, respectively. 
Volume-rendered side views of the bilayer cells were also presented (scale bar: 100 µm); (C) 
expression of the tight junction protein ZO-1 in the cocultured hiPSC-EC (scale bar: 100 µm 
for general view, and 20 µm for close view); (D) hiPSC-EC morphology on the electrospun 
PLGA mesh after 7 day coculture (scale bar: 50 µm); (E) TEER value of the empty mesh, 
without cells, in the transwell insert (white), BBB model with hiPSC-Astro alone (gray), and 
with coculture of hiPSC-ECs and hiPSC-Astro at different time points (black) (n = 3–5, **p 
< 0.01, $ indicates a significant difference between days 1 and 3, % indicates a significant 
difference between days 3 and 7); and (F) permeability coefficient of sodium fluorescein 
through the in vitro BBB model (n = 3–5, **p < 0.01).
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Figure 5. 
Barrier functions of the in vitro BBB model to PTX and BTZ: (A) schematic of a triculture 
of hiPSC-ECs and hiPSC-Astro on the PLGA mesh in the upper chamber with U87MG cells 
in the lower chamber of a transwell insert and the addition of PTX and BTZ. The upper 
chamber was filled with EGM and the lower chamber was filled with astrocyte medium; (B) 
typical images of U87MG response to the treatment of PTX (1 µg/mL) and BTZ (4 µg/mL) 
with or without the BBB model. Left one panel: optical images (scale bar: 100 µm); right 
four panels: IF staining images (scale bar: 100 µm); (C) LDH assay showed cytotoxicity (n = 
3, **p < 0.01); (D) MTT assay showed cell metabolic activity (n = 3, **p < 0.01); and (E) 
TEER value with changing the dose of PTX and BTZ (n = 3, **p < 0.01). The dashed line 
indicates the average TEER value without the addition of anti-GBM drugs.
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Figure 6. 
Barrier functions of the in vitro BBB model to Aβ: (A) schematic of a triculture of hiPSC-
ECs and hiPSC-Astro on the PLGA mesh in the upper chamber with hiPSC–NPCs in the 
lower chamber of a transwell insert and the addition of Aβ; hiPSC–NPCs were induced in 
neuronal differentiation medium for 14 days before triculture. The upper chamber was filled 
with EGM and the lower chamber was filled with neuronal differentiation medium; (B) 
typical images of hiPSC–NPC response to the treatment of Aβ with or without the BBB 
model. Left one panel: optical images (scale bar: 100 µm); right four panels: IF staining 
images (scale bar: 100 µm); and (C) LDH assay showed cytotoxicity (n = 3, *p < 0.05). 
Control indicates the group without electrospun meshes, hiPSC-ECs, hiPSC-Astro, and 
without Aβ treatment; the empty mesh indicates the group with electrospun meshes but 
without hiPSC-ECs, hiPSC-Astro, and with Aβ treatment; and the BBB model indicates the 
group with electrospun meshes, hiPSC-ECs, hiPSC-Astro, and with Aβ treatment.
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